CIK 0001746473
- Non-accelerated filer
- Smaller reporting company
PLIANT THERAPEUTICS, INC.
Sign in to watch- Ticker
- PLRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474272481
- Phone
- +1 650-481-6770
- Business address
- 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale General Counsel & Corp. Sec'y sold 7,751 shares at an average $26.62 ($206,329)
- 4 Planned sale Chief Medical Officer sold 11,245 shares at $26.52 ($298,228)
- 4 Planned sale Chief Business Officer sold 9,036 shares at $26.52 ($239,643)
- 4 Planned sale Chief Financial Officer sold 9,960 shares at $26.52 ($264,148)
- 4 Planned sale President and CEO sold 35,339 shares at $26.52 ($937,222)
- 4 Grant or award General Counsel & Corp. Sec'y acquired 13,593 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 21,874 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 17,578 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 19,375 shares (grant or award)
- 4 Grant or award President and CEO acquired 68,749 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President and CEO sold 30,000 shares at an average $33.91 ($1,017,430)
- 4 Open-market sale President and CEO sold 45,000 shares at an average $34.48 ($1,551,637)
- 4 Grant or award Chief Financial Officer acquired 54,000 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 54,000 shares (grant or award)
Page 6 of 11 · 215 filings